All Things Angioedema - Learning about Angioedema with Dr Thomas Buttgereit

Episode 17 – Unmet needs for HAE in Asia

Episode 17 – Unmet needs for HAE in Asia
Dr Thomas Buttgereit welcomes Dr Philip Li to discuss the unmet needs of people with HAE in Asia, including the lack of consensus guidelines for the management of HAE, the lack of suitable diagnostic tools, and limited access to treatment.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Epidemiology, management and treatment access of hereditary angioedema in the Asia pacific region; Screening for type II hereditary angioedema; and Hong Kong-Macau severe hives and angioedema referral pathway.

Episode 16 – ACE inhibitor-induced angioedema

Ear, nose and throat specialist Dr Robin Lochbaum joins Dr Thomas Buttgereit to discuss angiotensin-converting enzyme (ACE) inhibitor‑induced angioedema, including information on the incidence and mechanism of action, and antihypertensive treatment options.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Concomitant medication in patients with bradykinin-mediated angioedema – there’s more than ACE inhibitors; The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema; and Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors – a nationwide registry-based cohort study.

Episode 15 – Mast cell-mediated angioedema

“Should it be considered a part of chronic spontaneous urticaria?” Dr Thomas Buttgereit welcomes Dr Marta Ferrer Puga to talk about mast cell-mediated angioedema, including discussion of the international urticaria guidelines definition.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: A comparative study of sex distribution, autoimmunity, blood, and inflammatory parameters in chronic spontaneous urticaria with angioedema and chronic histaminergic angioedema; Angioedema severity and impact on quality of life: Chronic histaminergic angioedema versus chronic spontaneous urticaria; and Medical algorithm: Diagnosis and management of histaminergic angioedema.

Episode 14 - Collaboration in HAE

“There are a lot of doctors that should know about angioedema.” Ear, nose and throat specialist Dr Janina Hahn joins Dr Thomas Buttgereit to discuss the importance of implementing an interdisciplinary approach in HAE, including tips on overcoming challenges.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/.

Episode 13 – Angioedema in the paediatric population

“Children should be informed about their illness according to their age.” Professor Henriette Farkas joins Dr Thomas Buttgereit to discuss angioedema in children, covering acute treatment options and the differing symptoms between adults and children.  
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Results from the phase 3 SPRING study; International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency; and Diagnosing pediatric patients with hereditary C1-inhibitor deficiency.

Episode 12 – The HAE specialist: ‘Never give up’

“I want to take an extra step, just to make sure that we never give up and provide them with the care that they deserve to receive.” Dr Danny Cohn joins Dr Thomas Buttgereit to talk about the role of an HAE specialist providing long-term, often multigenerational care, including the benefits offered by ACARE centres.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: The Chronic Urticaria Registry (CURE).

Episode 11 – The perspective from India in treating paediatric patients

Dr Thomas Buttgereit is joined by Professor Ankur Kumar Jindal to discuss his experience as a paediatrician treating angioedema in India, covering the reoccurring challenges and how best to counsel families when discussing the risk of transmission to the next generation.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: P-49 Transmission patterns in C1-INH deficiency Hereditary Angioedema favours a wild-type male offspring: our experience at Chandigarh, India; Management of hereditary angioedema in resource-constrained settings: A consensus statement from Indian subcontinent; Screening for type II hereditary angioedema; Transmission patterns of C1-INH deficiency hereditary angioedema favours a wild-type male offspring and Epidemiology, management and treatment access of hereditary angioedema in the Asia pacific region.

Episode 10 – Who is behind the scenes of ACARE?

Dr Thomas Buttgereit is joined by Julia Föll and Reinhardt Britz to discuss the responsibilities of working within an ACARE office, covering audit criteria and ongoing ACARE projects.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Become an ACARE, ACARE LevelUp: The ACARE physician information and education platform and Programme for the identification of mutations in genes of patients with recurrent idiopathic or hereditary angioedema.

Episode 9 – The AURORA study

“In the past, they’ve used 72 different combinations of outcomes and outcome measures.” Remy Peterson joins Dr Thomas Buttgereit to discuss the need for the AURORA study, and shares the resulting consensus for acute treatment outcomes in HAE.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/.
Additional resources relating to the topics discussed in this episode can be found here: The registered study protocol: AcUte tReatment Outcomes in heReditary Angioedema (AURORA) and Outcome measures in randomized controlled studies of acute therapy for hereditary angioedema: A systematic review.

Episode 8 – The future of angioedema: Is there a cure on the horizon?

Join Dr Lauré Fijen and Dr Thomas Buttgereit as they discuss emerging angioedema treatments, covering efficacy, safety, frequency and route of administration. The experts also reflect on the possibility of a cure for HAE.
Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here.
For more information about the GA2LEN ACARE network and its activities please visit https://acare-network.com/. Additional resources relating to the topics discussed in this episode can be found here: Hereditary angioedema: The clinical picture of excessive contact activation and Current and prospective targets of pharmacologic treatment of hereditary angioedema types 1 and 2.